ProCE Banner Activity

Answering Your Questions About Tardive Dyskinesia

Podcast Episodes
Following recent live conferences, expert faculty answer your most asked questions on tardive dyskinesia screening and management.

Released: December 06, 2022

Expiration: December 05, 2023

Share

Faculty

Leslie Citrome

Leslie Citrome, MD, MPH

Clinical Professor
Department of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York

Charles DeBattista

Charles DeBattista, DMH, MD

Chief, Depression Research Clinic
Director, Medical Student Education in Psychiatry
Professor of Psychiatry and Behavioral Sciences
Stanford University School of Medicine
Stanford, California

Stuart Isaacson

Stuart Isaacson, MD

Director
Parkinson s Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida
Clinical Associate Professor of Neurology
FIU Herbert Wertheim College of Medicine
Miami, Florida

Greg W. Mattingly

Greg W. Mattingly, MD

Greg W. Mattingly, MD

Associate Clinical Professor

Department of Psychiatry

Washington University School of Medicine

President

St. Charles Psychiatry Associates

St. Louis, Missouri

Jonathan M. Meyer

Jonathan M. Meyer, MD

Voluntary Clinical Professor, Department of Psychiatry
University of California, San Diego
Psychopharmacology Consultant
Balboa Naval Medical Center First Episode Psychosis Program
State of Nevada Project ECHO First Episode Psychosis Program

Rajesh Pahwa

Rajesh Pahwa, MD

Chief, Parkinson and Movement Disorder Division
Director, Parkinson Foundation Center of Excellence
University of Kansas Medical Center
Kansas City, Kansas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Neurocrine Biosciences

Faculty Disclosure

Primary Author

Leslie Citrome, MD, MPH

Clinical Professor
Department of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York

Leslie Citrome, MD, MPH: consultant: AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Cerevel, Clinilabs, COMPASS, Eisai, Enteris BioPharma, HLS Therapeutics, Idorsia, INmune Bio, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Lyndra, Medavante-ProPhase, Marvin, Merck, Mitsubishi-Tanabe Pharma, Neurocrine, Neurelis, Novartis, Noven, Otsuka, Ovid, Praxis, Recordati, Relmada, Reviva, Sage, Sunovion, Supernus, Teva, University of Arizona; speaker: AbbVie/Allergan, Acadia, Alkermes, Angelini, Axsome, BioXcel, Eisai, Idorsia, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Recordati, Sage, Sunovion, Takeda, Teva, Medscape, NACCME, NEI, Vindico; stocks/stock options: Bristol-Myers Squibb, Johnson & Johnson, Lilly, Merck, Pfizer, Reviva.

Charles DeBattista, DMH, MD

Chief, Depression Research Clinic
Director, Medical Student Education in Psychiatry
Professor of Psychiatry and Behavioral Sciences
Stanford University School of Medicine
Stanford, California

Charles DeBattista, DMH, MD: researcher: Biolite, Compass, Janssen, Myriad, Neurocentia, Relmada, Sage; consultant: AbbVie, Corcept.

Stuart Isaacson, MD

Director
Parkinson s Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida
Clinical Associate Professor of Neurology
FIU Herbert Wertheim College of Medicine
Miami, Florida

Stuart Isaacson, MD: consultant/advisor/speaker: Neurocrine, Supernus, Teva.

Greg W. Mattingly, MD

Greg W. Mattingly, MD

Associate Clinical Professor

Department of Psychiatry

Washington University School of Medicine

President

St. Charles Psychiatry Associates

St. Louis, Missouri

Greg W. Mattingly, MD: speaker: AbbVie, Alkermes, Corium, Eisai, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Tris Pharma; consultant: AbbVie, Acadia, Alkermes, Axsome, Corium, Eisai, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neos, Neurocrine, Noven, Otsuka, Redax, Rhodes, Roche, Sage, Sirona, Sunovion, Supernus, Takeda, Teva, Tris Pharma; researcher: AbbVie, Acadia, Akili, Alkermes, Axsome, Boehringer, Emalex, Idorsia, Janssen, Karuna, Lumos Labs, Medgenics, NLS-1 Pharma AG, Redax, Relmada, Roche, Sage, Sirtsei, Sunovion, Supernus, Takeda, Teva.

Jonathan M. Meyer, MD

Voluntary Clinical Professor, Department of Psychiatry
University of California, San Diego
Psychopharmacology Consultant
Balboa Naval Medical Center First Episode Psychosis Program
State of Nevada Project ECHO First Episode Psychosis Program

Jonathan M. Meyer, MD: consultant/advisor/speaker: Alkermes, Intra-Cellular Therapies, Karuna, Neurocrine, Noven, Otsuka America, Sunovion, Teva.

Rajesh Pahwa, MD

Chief, Parkinson and Movement Disorder Division
Director, Parkinson Foundation Center of Excellence
University of Kansas Medical Center
Kansas City, Kansas

Rajesh Pahwa, MD: consultant/advisor/speaker: Abbott, AbbVie, ACADIA, Acorda, Amneal, Artemida, Britannia, Cala Health, Global Kinetics, Impel, Insightec, Jazz, Kyowa, Neurocrine, Neuropharma, PhotoPharmics, Sage, SciNeuro, Sunovion, Supernus, XwPharma; researcher: Abbott, AbbVie, Addex, Biogen, Biohaven, Boston Scientific, EIP, Global Kinetics, Impax, Intec, Lilly, Neuroderm, Neuraly, Parkinson’s Foundation, Pharma 2B, Prelinia, Roche, Sage, SIS, Sun Pharma, Sunovion, Theranexus, Theravance, Voyager.